Stocks Health care BVS
NASDAQ · Health careBioventus Inc. (BVS)
Bioventus Inc. brought in $585.6M of revenue over the twelve months to September 26, 2026, up 3.9% from a year earlier. Net income was $57.3M, a net margin of 9.8%. Operating cash flow minus capital spending left $72.1M of free cash flow in fiscal 2025. At September 26, 2026 it held $30.7M in cash against $229.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 2, 2026.
Key facts about Bioventus Inc.
- Net worth
- Bioventus Inc. has a market value (market cap) of $926.3M at the latest share price, and shareholders' equity of $240.5M on its balance sheet at September 26, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $568.1M (-0.9% year on year), with net income of $22.7M. Over the 12 months to September 26, 2026: revenue $585.6M, net income $57.3M.
- Cash flow
- In fiscal 2025 operations brought in $74.7M of cash; after $2.6M of capital spending, free cash flow was $72.1M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 2, 2026 and covers the period to September 26, 2026. Open on SEC EDGAR
- Next earnings report
- Bioventus Inc.'s next report is expected around March 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Bioventus Inc. does
Bioventus Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker BVS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $568.1M | $22.7M | $0.33 | $72.1M |
| 2024 | $573.3M | -$36.1M | -$0.56 | $37.8M |
| 2023 | $512.3M | -$156.2M | -$2.49 | $8M |
| 2022 | $512.1M | -$158.7M | -$2.59 | -$15M |
| 2021 | $430.9M | $19.4M | -$0.15 | $9.5M |
| 2021 | $321.2M | $16.4M | n/a | $55.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where BVS ranks in Health care
Latest SEC filings
What Bioventus Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 2, 2026Quarterly report 10-Q · period to September 26, 2026Revenue rose 2.7% to $142.4M versus the same quarter last year; diluted EPS $0.08 versus $0.05.
- November 2, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026Quarterly report 10-Q · period to June 27, 2026Revenue rose 3.8% to $153.2M versus the same quarter last year; diluted EPS $0.47 versus $0.11.
- August 5, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- June 4, 2026
- May 29, 2026
- May 21, 2026
- May 6, 2026Quarterly report 10-Q · period to March 28, 2026Revenue rose 6.6% to $132.1M versus the same quarter last year; diluted EPS $0.04 versus -$0.04.
What is BVS worth? A DCF from its reported cash flow
Insider trades
What the people running Bioventus Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 2, 2026 | Sutter Martin PDirector, 10% owner | Exercised options | 32,282 | - |
| June 2, 2026 | Hawkins William ADirector | Exercised options | 39,789 | - |
| June 2, 2026 | Nohra Guy PDirector | Exercised options | 32,282 | - |
| June 2, 2026 | Stalnecker Susan MDirector | Exercised options | 32,282 | - |
| June 2, 2026 | Neels Guido JDirector | Exercised options | 32,282 | - |
| June 2, 2026 | Bartholdson John A.Director, 10% owner | Exercised options | 32,282 | - |
| June 2, 2026 | Beyer PatDirector | Exercised options | 32,282 | - |
| June 2, 2026 | Cowdy Philip G.Director | Exercised options | 32,282 | - |
Who owns BVS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 9.03% | February 13, 2026 |
Largest institutional holders
Insiders
14 insiders reported holding 1,804,057 shares in total, about $19.9M at the last price.
| Holder | Shares |
|---|---|
| Hawkins William ADirector | 297,640 |
| Singleton Mark LeonardSVP & CFO | 177,333 |
| D'Adamio AnthonySVP & General Counsel | 153,655 |
| Nohra Guy PDirector | 148,892 |
| Stalnecker Susan MDirector | 138,239 |
| Claypoole Robert EPresident and CEO, Director | 135,944 |
| Sutter Martin PDirector, 10% owner | 117,523 |
| Neels Guido JDirector | 117,523 |
| Bartholdson John A.Director, 10% owner | 111,902 |
| Ladone Mary KayDirector | 111,263 |
Questions about BVS
What does Bioventus Inc. do?
Bioventus Inc. is a company in the Health care sector, listed on NASDAQ as BVS. Its shares trade on NASDAQ under the ticker BVS.
What is Bioventus Inc.'s net worth?
Bioventus Inc. has a market value (market cap) of $926.3M at the latest share price, and shareholders' equity of $240.5M on its balance sheet at September 26, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Bioventus Inc. profitable?
Yes. Over the twelve months to September 26, 2026 it reported net income of $57.3M on revenue of $585.6M, a net margin of 9.8%.
How much revenue does Bioventus Inc. make?
Over the twelve months to September 26, 2026 Bioventus Inc. reported revenue of $585.6M. That is 3.9% more than a year earlier.
When did Bioventus Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 2, 2026. It covers the period to September 26, 2026.
When is Bioventus Inc.'s next earnings report?
Bioventus Inc.'s next report is expected around March 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare BVS with
Follow BVS
Get an email when Bioventus Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Bioventus Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.